Search - tctmd.com

Displaying 241 - 260 of 407

Sort: Relevancy | Date

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session

June 26, 2020

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

Todd Neale

May 13, 2020

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

L.A. McKeown

April 07, 2020

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Shelley Wood

March 30, 2020

News Conference News ACC 2020

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

Yael L. Maxwell

March 19, 2020

News Conference News

ACC, EHRA Cancel 2020 Meetings Over COVID-19

Michael O'Riordan

March 09, 2020

News Daily News

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

Shelley Wood

February 26, 2020

News Daily News

MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR

Michael O'Riordan

February 13, 2020

News Daily News

Kidney Transplant Boosts CV Functional Reserve

Todd Neale

February 07, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Industry News

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

November 06, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

Advertisement

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Intact Vascular Announces Positive One-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session

Subcutaneous ICD Holds Up Well Against Transvenous Devices

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity

ACC, EHRA Cancel 2020 Meetings Over COVID-19

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR

Kidney Transplant Boosts CV Functional Reserve

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Has Benefits Across Heart Failure Subgroups

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content